Zero-shot Learning (ZSL) enables classifiers to recognize classes unseen during training, commonly via generative two stage methods: (1) learn visual semantic correlations from seen classes; (2) synthesize unseen class features from semantics to train classifiers. In this paper, we identify spurious visual semantic correlations in existing generative ZSL worsened by scarce seen class samples and introduce two metrics to quantify spuriousness for seen and unseen classes. Furthermore, we point out a more critical bottleneck: existing unadaptive fully noised generators produce features disconnected from real test samples, which also leads to the spurious correlation. To enhance the visual-semantic correlations on both seen and unseen classes, we propose ZeroDiff++, a diffusion-based generative framework. In training, ZeroDiff++ uses (i) diffusion augmentation to produce diverse noised samples, (ii) supervised contrastive (SC) representations for instance level semantics, and (iii) multi-view discriminators with Wasserstein mutual learning to assess generated features. At generation time, we introduce (iv) Diffusion-based Test time Adaptation (DiffTTA) to adapt the generator using pseudo label reconstruction, and (v) Diffusion-based Test time Generation (DiffGen) to trace the diffusion denoising path and produce partially synthesized features that connect real and generated data, and mitigates data scarcity further. Extensive experiments on three ZSL benchmarks demonstrate that ZeroDiff++ not only achieves significant improvements over existing ZSL methods but also maintains robust performance even with scarce training data.
Zihan Ye, S. Gowda, Kaile Du et al.· IEEE Transactions on Pattern...· 0 citations
Test-time adaptation (TTA) has become a practical way to adapt deployed models to unlabeled target data, a setting that is especially relevant in computational pathology where staining, scanner, and cohort shifts are routine. While most TTA methods are evaluated by their effect on accuracy, clinical use also depends on whether the model's explanations remain reliable after adaptation. In this paper, we take a closer look at this largely unmeasured effect. We study explanation stability under TTA across two histopathology benchmarks, Camelyon17 and NCT CRC-HE, using five architectures ranging from convolutional networks to vision transformers and a pathology foundation model, seventeen TTA methods, and four attribution families. Across 2,958 adaptation runs, we observe a clear and systematic pattern: TTA methods differ sharply in how much they move model explanations, with frozen-backbone methods leaving attributions almost unchanged and continual methods such as CoTTA and RoTTA causing the largest drift. This effect is not uniform. Convolutional networks are substantially more sensitive than transformer and foundation-model backbones, and explanation drift increases with adaptation strength while remaining largely insensitive to batch size. Surprisingly, explanation stability is only weakly coupled to adaptation quality. Some methods preserve explanations almost perfectly while degrading calibration or accuracy, producing silent failures that would be missed by accuracy-only or explanation-only evaluation. These findings show that explanation stability is a distinct reliability axis for TTA in computational pathology. We release the metric, protocol, and full benchmark to support future work on adaptation methods that are not only accurate, but also stable and clinically auditable. Code: https://github.com/bahumanyarg11/tta-explanation-stability-pipeline
R. G. Bahumanya, M. HarshithV., S. Gowda et al.· 0 citations
CARE is introduced, a closed-form concept erasure operator that replaces the raw target direction with a kept-subspace-aware direction computed from a small bank of retained concept anchors, and preserves non-target concepts more faithfully while maintaining competitive erasure across instance, style, and celebrity concepts.
Parth Upman, Nishita Jain, S. Gowda· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
